Home > Insider Trading > Filing (0001567619-20-018010)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1799448	Aligos Therapeutics Inc.	ALGS	()	1231

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1618788	Vivo Capital Fund Viii, L.p.	C/O Vivo Capital Llc 192 Lytton Avenue Palo Alto CA 94301	No	No	Yes	No
1618789	Vivo Capital Viii, Llc	C/O Vivo Capital Llc 192 Lytton Avenue Palo Alto CA 94301	No	No	Yes	No
1628048	Vivo Capital Surplus Fund Viii, L.p.	C/O Vivo Capital Llc 192 Lytton Avenue Palo Alto CA 94301	No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2020-10-20	1,885,611	$0.00	1,885,611	No	4	C	Indirect	Vivo Capital Fund VIII, L.P.
Common Stock	Acquisiton	2020-10-20	523,726	$0.00	2,409,337	No	4	C	Indirect	Vivo Capital Fund VIII, L.P.
Common Stock	Acquisiton	2020-10-20	224,054	$0.00	2,633,391	No	4	C	Indirect	Vivo Capital Fund VIII, L.P.
Common Stock	Acquisiton	2020-10-20	260,380	$0.00	260,380	No	4	C	Indirect	Vivo Capital Surplus Fund VIII, L.P.
Common Stock	Acquisiton	2020-10-20	72,320	$0.00	332,700	No	4	C	Indirect	Vivo Capital Surplus Fund VIII, L.P.
Common Stock	Acquisiton	2020-10-20	30,939	$0.00	363,639	No	4	C	Indirect	Vivo Capital Surplus Fund VIII, L.P.
Common Stock	Acquisiton	2020-10-20	483,267	$15.00	3,116,658	No	4	P	Indirect	Vivo Capital Fund VIII, L.P.
Common Stock	Acquisiton	2020-10-20	66,733	$15.00	430,372	No	4	P	Indirect	Vivo Capital Surplus Fund VIII, L.P.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	Vivo Capital Fund VIII, L.P.
No	4	C	Indirect	Vivo Capital Fund VIII, L.P.
No	4	C	Indirect	Vivo Capital Fund VIII, L.P.
No	4	C	Indirect	Vivo Capital Surplus Fund VIII, L.P.
No	4	C	Indirect	Vivo Capital Surplus Fund VIII, L.P.
No	4	C	Indirect	Vivo Capital Surplus Fund VIII, L.P.
No	4	P	Indirect	Vivo Capital Fund VIII, L.P.
No	4	P	Indirect	Vivo Capital Surplus Fund VIII, L.P.

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Preferred Stock	Disposition	2020-10-20	1,885,611	$0.00	1,885,611	$0.00
Common Stock	Series A Preferred Stock	Disposition	2020-10-20	260,380	$0.00	260,380	$0.00
Common Stock	Series B-1 Preferred Stock	Disposition	2020-10-20	523,726	$0.00	523,726	$0.00
Common Stock	Series B-1 Preferred Stock	Disposition	2020-10-20	72,320	$0.00	72,320	$0.00
Common Stock	Series B-2 Preferred Stock	Disposition	2020-10-20	224,054	$0.00	224,054	$0.00
Common Stock	Series B-2 Preferred Stock	Disposition	2020-10-20	30,939	$0.00	30,939	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect

Footnotes

Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date.
Vivo Capital VIII, LLC ("Vivo LLC") is the general partner of each of Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P., the record holder of the securities. Frank Kung, Edgar Engleman and Shan Fu are managing members of Vivo LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed ad admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.